Biogen (BIIB) Current Deferred Revenue (2010 - 2012)
Biogen's Current Deferred Revenue came in at $110.3 million for Q2 2012, up 14.9% from the prior quarter.
Powered by 
Analysis
Biogen (BIIB) Current Deferred Revenue (2010 - 2012) Analysis & Trends
At the end of FY2011, Biogen's Current Deferred Revenue was $69.6 million, up 68.5% from FY2010.
- Going back by year, Current Deferred Revenue was $41.3 million in FY2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,137.66 Bn | 1,106.24 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 636.13 Bn | 556.00 Bn | 17.30 Bn |
| 3 | AbbVie | 505.28 Bn | 478.39 Bn | 12.70 Bn |
| 4 | Merck | 358.10 Bn | 312.48 Bn | 12.21 Bn |
| 5 | Novartis Ag | 292.59 Bn | 256.58 Bn | 11.24 Bn |
| 6 | Astrazeneca | 265.81 Bn | 239.50 Bn | 12.86 Bn |
| 7 | Amgen | 237.53 Bn | 192.93 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn |
| 9 | Pfizer | 171.17 Bn | 117.82 Bn | 10.94 Bn |
| 10 | Biogen | 36.99 Bn | 23.65 Bn | 1.96 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2012 | 110.30 Mn |
| Mar 31, 2012 | 96.00 Mn |
| Dec 31, 2011 | 69.60 Mn |
| Dec 31, 2010 | 41.30 Mn |
API Access
Biogen Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=BIIB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "BIIB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=BIIB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();